NEW POSSIBILITIES OF PHARMACOTHERAPY FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE

D.Ruziboeva; D.Ruziboeva; S.Baxodirov; M.Ruziboeva

doi:10.5281/zenodo.7308725

NEW POSSIBILITIES OF PHARMACOTHERAPY FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE

09.11.2022 International Scientific Journal "Science and Innovation". Series D. Volume 1 Issue 7

D.Ruziboeva , D.Ruziboeva , S.Baxodirov , M.Ruziboeva

Abstract. The use of bronchodilators (DB) remains up to the present day the leading therapeutic strategy for the treatment of chronic obstructive pulmonary disease (COPD), in which case administration of fixed-dose combinations of long-acting bronchodilators seem the most promising. At the same time, the issues of anti-inflammatory therapy of COPD are also actively discussed, first of which is feasibility for the wide use of fixed-dose combinations of inhaled glucocorticosteroids (IHGC) with long-acting β2-agonists (LABA). Recent years are characterized by the launch of a significant number of new BDs, anti-inflammatory drugs and their combinations to the pharmaceutical market. The article considers the role and place of new drugs in the treatment of COPD having a stable course.

Keywords: chronic obstructive pulmonary disease, pharmacotherapy, vilenterol/umeclidinium, vilantherol / fluticasone furoate.

References:

1. Diaz-Guzman E, Mannino DM. Epidemiology and prevalence of chronicobstructive pulmonary disease. Clin Chest Med, 2014, 35(1): 7–16. 2. Marchetti N, Criner GJ, Albert RK. Preventing acute exacerbations and hospital admissions in COPD. Chest, 2013, 143(5): 1444–1454. 3. Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease (Update 2018). Available from: http: //www.goldcopd.org/. 4. Barrecheguren M, Monteagudo M, Ferrer J, et al. Treatment patterns in COPD patients newly diagnosed in primary care. A population-based study. Respir Med, 2016, 111: 47–53. 5. Aрхипов В.В., Aрхиповa Д.Е., Стукaлинa Е.Ю. и соaвт. Чaстотa встречaемости отдельных фенотипов хронической обструктивной болезни легких в Российской Федерaции, их хaрaктеристики и подходы к лечению. Прaктическaя пульмонология, 2016, 3: 20–25. /Arkhipov VV, Arkhipova DE, Stukalina EYu, et al. Frequency of separate phenotypes of chronic obstructive pulmonary disease in the Russian Federation, characteristics and approaches to treatment. Prakticheskaya Pulmonologiya, 2016, 3: 20-25. 6. Ohar JA, Donohue JF. Mono-and combination therapy of long-acting bronchodilators and inhaled corticosteroids in advanced COPD. Semin Respir Crit Care Med, 2010, 31: 321–333. 7. Российское респирaторное общество. Хроническaя обструктивнaя болезнь легких. Клинические рекомендaции (пересмотр 2018 годa). /Russian Respiratory Society. Chronic obstructive pulmonary disease. Clinical guidelines (2018 revision). http: //spulmo.ru/obrazovatelnyeresursy/federalnye-klinicheskie-rekomendatsii/. 8. Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med, 2007, 356(8): 775–789. 9. Wilchesky M, Ernst P, Brophy JM, et al. Bronchodilator use and the risk of arrhythmia in COPD: part 2: reassessment in the larger Quebec cohort. Chest, 2012, 142: 305-311. 10. Korn S, Kerwin E, Atis S, et al. Indacaterol oncedaily provides superior efficacy to salmeterol twice-daily in COPD: a 12-week study. Respir Med, 2011, 105(5): 719–726. 11. Donohue JF, Fogarty C, Lötvall J, et al. Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium. Am J Respir Crit Care Med, 2010, 182(2): 155–162. 12. Ferguson GT, Feldman GJ, Hofbauer P, et al. Efficacy and safety of olodaterol once daily delivered via Respimat® in patients with GOLD